Objective To develop a new method with using surgical procedures for multiple correction of nasal deformity with cleft lip and palate.Methods Our operation procedures included elevation of the nasal floor depression in cleft side with the transplantation of autogenous cancellous bone, frustration and elevation of the nasal bone and part of the frontal process of maxilla, and replacement of septum between alar cartilages.Through these procedures, the nasal deformity could be multiply corrected.Results Postoperative follow up for 1～8years in 45 patients demonstrated satisfactory results. Conclusion Multiple correction is a new method of treatment for nasal deformity with cleft lip and palate.

Objective To investigate the relationship between the the expression of SOCS-1/3 in the peripheral blood mononuclear cells (PBMCs) and interferon therapeutic response in patients with chronic hepatitis B.Methods 50 patients with chronic hepatitis B were given interferon therapy.After 24 weeks treatment,according to biochemical and virologic response,they were divided into two groups:response and non response group.HBV-DNA was detected by PCR.The SOCS-1/3 mRNA levels were measured by RT-PCR.Results The expression of SOCS-1 in the PBMCs of response group after 24 weeks treatment was significantly higher than that before interferon therapy (P ＜ 0.05).The expression of SOCS-3 in the PBMCs of response group after 24 weeks trentment was significantly lower than that before interferon therapy (P ＜ 0.05).In non response group,there were no significant differences in the expression of SOCS-1/3 (P ＞ 0.05).Conclusion The increase expression of SOCS-1 mRNA and the decrease of SOCS-3 mRNA in the PBMCs in chronic hepatitis B patients received 24 weeks interferon-therapy probably is relevant to the IFN-α antiviral effect.

Objective To investigate the relationship between the serum chemokine IP-10 and RANTES levels and Interferon therapeutic early response in patients with chronic hepatitis B(CHB).Methods 50 patients with chronic hepatitis B were chosen into interferon therapy.After 12 weeks,they were devided into three groups:complete response A、partial response B、non response C group.HBV-DNA was detected by PCR;The serum chemokines( IP-10 and RANTES) were measured by Luminex Liquichip technology.Results The base HBV DNA and RANTES levels of three groups weren't significantly different (P ＜0.05) ;The base ALT and IP-10 levels of A group were significantly higher than that in B and C group( P ＜ 0.05).The IP-10、RANTES contents of A group in therapeutic 4th week were significantly lower than that before interferon therapy(P ＜ 0.05 );There were no significant differences in B、C group (P ＞0.05) ;The levels changes of IP-10、RANTES、HBV DNA and ALT in therapeutic 12th week were significantly different between the three groups ( P ＜ 0.05 ),The level of ALT in 50 patients has positive correlation with IP-10 level (P ＜ 0.05) ;The level of HBV DNA in 50 patients had positive correlation with RANTES level( P ＜ 0.05 ) ;The base level of IP-10 had positive correlation with the change of HBV-DNA contents in therapeutic 12th week( P ＜0.05 ) ;The change of ALT level in reponse patients in therapeutic 12th week had positive correlation with the change of IP-10 、RANTES levels( P ＜ 0.05 ).Conclusion The decrease of IP-10,RANTES level in CHB patients received 12weeks interferon-α therapy could lead to reduce liver inflammation;The base IP-10 level probably was relevant to the early response in CHB patients received interferon-α therapy.

ObjectiveTo observe the treatment effects in 48 cases of advanced lung cancer patients,with the immune therapy of the dendritic cells loading of tumor autologous antigen (DCTAA) combining with the cells induced factor of the killer cells(CIK)from the matched umbilical cord blood cells.MethodsThe peripheral blood mononuclear cell(PBMC)from the matched umbilical cord blood cells was seperated,and induced to CIK and DC with some cytokines in vitro, such as CD3McAb, IL-2, IFN-γ IL-1α, etc. After 12 to 15 days, the amplified CIK cells obtained were obtained, with the strict quality control, infused the CIK cells to the patients body back in six times,about(5-8)×109 CIK cells in each time.In the fifth day of the cultivation,DETAA cells were loaded and DCTAA cells were collected in the eighth day,and then hypodermic injection was done. The patient' s general situation after the immune treatment was observed, such as the size of the tumors, clinical symptom score, the quality of life and immune indexes. Karnofsky score, weight, toxic side effects and the patient's survival were also studied.ResultsIn the 48 cases with the DCTAA-CIK treatment, complete remission (CR), partial remission (PR)was 37 cases, the overall remission rate was 77.1％. The improvement rate of clinical symptom scores was from 78.9 ％ to 84.7 ％, the increasing rate of Karnofsky score was 89.6 ％ (43/48). 1-year survival reached to 80.6 ％. There were significant difference in little toxic side effects(P ＜ 0.01). The proportion of CD3, CD4 and NK cells in peripheral blood cells increased significantly (P ＜ 0.01) after DCTAA-CIK cells treatment[(42.21±6.12)％, (24.42±3.01)％, 0.99±0.34, (24.98±3.02) ％; (71.58±7.64) ％, (37.25±2.13) ％, 1.62±0.45, (35.23±4.11) ％](t = 6.34, 5.67, 0.25, 4.43, P ＜0.01).ConclusionThe DCTAA-CIK immune therapy is benefit for advanced lung cancer,not only improve the immune function but also ameliorate the clinical symptoms.

Coronavirus disease 2019 (COVID-19) is now pandemic worldwide and has heavily overloaded hospitals in Wuhan City, China during the time between late January and February. We reported the clinical features and therapeutic characteristics of moderate COVID-19 cases in Wuhan that were treated via the integration of traditional Chinese medicine (TCM) and Western medicine. We collected electronic medical record (EMR) data, which included the full clinical profiles of patients, from a designated TCM hospital in Wuhan. The structured data of symptoms and drugs from admission notes were obtained through an information extraction process. Other key clinical entities were also confirmed and normalized to obtain information on the diagnosis, clinical treatments, laboratory tests, and outcomes of the patients. A total of 293 COVID-19 inpatient cases, including 207 moderate and 86 (29.3%) severe cases, were included in our research. Among these cases, 238 were discharged, 31 were transferred, and 24 (all severe cases) died in the hospital. Our COVID-19 cases involved elderly patients with advanced ages (57 years on average) and high comorbidity rates (61%). Our results reconfirmed several well-recognized risk factors, such as age, gender (male), and comorbidities, as well as provided novel laboratory indications (e.g., cholesterol) and TCM-specific phenotype markers (e.g., dull tongue) that were relevant to COVID-19 infections and prognosis. In addition to antiviral/antibiotics and standard supportive therapies, TCM herbal prescriptions incorporating 290 distinct herbs were used in 273 (93%) cases. The cases that received TCM treatment had lower death rates than those that did not receive TCM treatment (17/273 = 6.2% vs. 7/20= 35%, P = 0.0004 for all cases; 17/77= 22% vs. 7/9= 77.7%, P = 0.002 for severe cases). The TCM herbal prescriptions used for the treatment of COVID-19 infections mainly consisted of Pericarpium Citri Reticulatae, Radix Scutellariae, Rhizoma Pinellia, and their combinations, which reflected the practical TCM principles (e.g., clearing heat and dampening phlegm). Lastly, 59% of the patients received treatment, including antiviral, antibiotics, and Chinese patent medicine, before admission. This situation might have some effects on symptoms, such as fever and dry cough. By using EMR data, we described the clinical features and therapeutic characteristics of 293 COVID-19 cases treated via the integration of TCM herbal prescriptions and Western medicine. Clinical manifestations and treatments before admission and in the hospital were investigated. Our results preliminarily showed the potential effectiveness of TCM herbal prescriptions and their regularities in COVID-19 treatment.
Adult ; Aged ; Aged, 80 and over ; COVID-19/therapy* ; China ; Combined Modality Therapy ; Drugs, Chinese Herbal/therapeutic use* ; Female ; Hospitalization ; Humans ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Retrospective Studies ; Survival Rate ; Treatment Outcome